SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: cknox who wrote (72)9/30/1998 11:01:00 PM
From: burner  Read Replies (1) of 134
 
Phase II primate study nearing completion

Immune Network Research Ltd IMM
Shares issued 19,970,452 Sep 22 close $0.17
Wed 23 Sept 98 News Release
Mr. Victor Jones reports
The phase II primate study of the company's proprietary monoclonal antibody
1F7 on the immune systems of SHIV infected and control primates is nearing
completion and now includes a second series of injections of mAb 1F7. The
encouraging condition of the primates during the six month study of mAb 1F7
has allowed the study to be expanded to model repeated administration of
mAb 1F7. Analysis of viral levels during the entire study is scheduled and
will provide predictive information, as it is a recognized model of HIV
disease in humans. The next milestone is the application for the human
trial of mAb 1F7 under an investigational new drug protocol.
Data from the six month primate study will be used to evaluate whether
using mAb 1F7 to strengthen the immune system response to HIV infection
lowers plasma virus load. In an earlier study, beneficial effects on the
immune system of SHIV infected macaques were reported and mAb 1F7
normalized the immune response against the viral infection in the monkeys.
Results from the current study will also assist with defining the selection
criteria for the human IND trial of mAb 1F7.
The private placement announced earlier has closed with subscriptions for
400,000 units priced at 20 cents per unit for a total of $80,000. In
response to increased investor interest, Peter Laipnieks has been appointed
director - investor relations for the company. The board of directors has
granted Mr. Laipnieks an option to purchase 150,000 shares at 15 cents for
five years. The board has also approved the transfer of 500,000 escrow
shares between a director and an officer. In addition, Alliance Corporate
Services, a Victoria based investor relations group, has been retained to
assist with investor relations activities as the company looks towards
reporting study results and financing clinical trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News